Phase 1/2 study of combined BCL-xL and MEK inhibition with navitoclax and trametinib in KRAS or NRAS mutant advanced solid tumors

CONCLUSIONS: Navitoclax in combination with trametinib was tolerable. Durable clinical responses were observed in patients with RAS-mutant GYN cancers, warranting further evaluation in this population.PMID:38456660 | DOI:10.1158/1078-0432.CCR-23-3135

Source: Clinical Colorectal Cancer - March 8, 2024 Category: Cancer & Oncology Authors: Ryan B Corcoran Khanh T Do Jeong E Kim James M Cleary Aparna R Parikh Oladapo O Yeku Niya Xiong Colin D Weekes Jennifer Veneris Leanne G Ahronian Gianluca Mauri Jun Tian Bryanna L Norden Alexa G Michel Emily E Van Seventer Giulia Siravegna Kyle Camphausen Source Type: research